In non-urothelial carcinomas, however, RAS mutations are infrequent and other mutations come into play (p16 & p15 deletion [31], [32], Bax, Bak & EGFR overexpression and p53 inactivation [32]). This evidence concerns the gene BAK1 and urothelial carcinoma.